• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of people who are depressed. A customized treatment could be the answer.

Cue why is cbt used in the treatment of depression an intervention platform that transforms sensors that are passively gathered from smartphones into customized micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each person, using Shapley values to discover their features and predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. To improve the outcomes, clinicians need to be able to recognize and treat patients who have the highest likelihood of responding to specific treatments.

The treatment of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from specific treatments. They make use of mobile phone sensors as well as a voice assistant that incorporates artificial intelligence, and other digital tools. With two grants awarded totaling more than $10 million, they will employ these techniques to determine the biological and behavioral factors that determine responses to antidepressant medications as well as psychotherapy.

The majority of research conducted to the present has been focused on clinical and sociodemographic characteristics. These include demographic factors such as age, sex and education, clinical characteristics such as the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

Few studies have used longitudinal data in order to predict mood in individuals. They have not taken into account the fact that moods vary significantly between individuals. It is therefore important to develop methods that allow for the identification and quantification of personal differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to detect patterns of behavior and emotions that are unique to each individual.

The team also developed an algorithm for machine learning to create dynamic predictors for each person's depression mood. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. The correlation was not strong, however (Pearson r = 0,08; P-value adjusted for BH = 3.55 10 03) and varied greatly among individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world1, but it is often untreated and misdiagnosed. Depression disorders are rarely treated due to the stigma attached to them and the lack of effective interventions.

To help with personalized treatment, it is essential to determine the predictors of symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only identify a handful of features associated with depression.

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements as well as capture a variety of unique behaviors and activity patterns that are difficult to document through interviews.

The study included University of California Los Angeles (UCLA) students experiencing mild to severe depression symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were referred to online support or clinical care depending on the degree of their menopause Depression treatment. Patients who scored high on the CAT-DI scale of 35 65 students were assigned online support via the help of a coach. Those with scores of 75 patients were referred for psychotherapy in-person.

At the beginning, participants answered an array of questions regarding their personal characteristics and psychosocial traits. The questions covered age, sex and education as well as financial status, marital status and whether they were divorced or not, current suicidal thoughts, intentions or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale of zero to 100. The CAT-DI assessment was conducted every two weeks for those who received online support and weekly for those who received in-person support.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are focused on finding predictors, which can help clinicians identify the most effective drugs for each person. Particularly, pharmacogenetics can identify genetic variations that affect the way that the body processes antidepressants. This allows doctors to select drugs that are likely to be most effective for each patient, reducing the time and effort involved in trial-and-error treatments and eliminating any side effects that could otherwise slow the progress of the patient.

Another approach that is promising is to create prediction models combining the clinical data with neural imaging data. These models can be used to identify the variables that are most predictive of a particular outcome, such as whether a drug will improve symptoms or mood. These models can also be used to predict a patient's response to a treatment they are currently receiving which allows doctors to maximize the effectiveness of their current therapy.

A new era of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables to improve predictive accuracy. These models have shown to be effective in the prediction of treatment outcomes like the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for future clinical practice.

Research into the underlying causes of depression continues, as well as ML-based predictive models. Recent findings suggest that depression is related to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will be based upon targeted therapies that restore normal functioning to these circuits.

Internet-based interventions are an option to accomplish this. They can provide more customized and personalized experience for patients. One study found that an internet-based program improved symptoms and provided a better quality life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to treating depression and treatment showed steady improvement and decreased adverse effects in a significant percentage of participants.

Predictors of Side Effects

In the treatment of depression the biggest challenge is predicting and determining the antidepressant that will cause minimal or zero side negative effects. Many patients take a trial-and-error method, involving various medications prescribed before finding one that is effective and tolerable. Pharmacogenetics provides an exciting new way to take an efficient and specific approach to choosing antidepressant medications.

There are several variables that can be used to determine the antidepressant to be prescribed, such as gene variations, phenotypes of patients such as ethnicity or gender and the presence of comorbidities. To identify the most reliable and valid predictors for a particular treatment, random controlled trials with larger numbers of participants will be required. This is because it could be more difficult to determine moderators or interactions in trials that comprise only one episode per person rather than multiple episodes over a long period of time.

Additionally, the prediction of a patient's reaction to a specific medication will also likely require information about the symptom profile and comorbidities, as well as the patient's personal experiences with the effectiveness and tolerability of the medication. At present, only a handful of easily assessable sociodemographic variables and clinical variables are reliable in predicting the response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

There are many challenges to overcome when it comes to the use of pharmacogenetics to treat depression. first line treatment for anxiety and depression, it is essential to be able to comprehend and understand the definition of the genetic factors that cause depression, as well as a clear definition of an accurate predictor of treatment response. Ethics such as privacy and the ethical use of genetic information should also be considered. In the long term pharmacogenetics can provide an opportunity to reduce the stigma that surrounds mental health treatment and improve the outcomes of those suffering with depression. As with any psychiatric approach it is crucial to give careful consideration and implement the plan. At present, the most effective option is to offer patients various effective medications for depression and encourage them to talk freely with their doctors about their experiences and concerns.